Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers

Clinical Pharmacokinetics

Volumn 55, Issue 8, 2016, Pages 1003-1014

  Polepally, Akshanth R ^a   King, Jennifer R ^a   Ding, Bifeng ^a   Shuster, Diana L ^a   Dumas, Emily O ^a   Khatri, Amit ^a   Chiu, Yi Lin ^a   Podsadecki, Thomas J ^a   Menon, Rajeev M ^a  

^a ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARISOPRODOL; COTRIMOXAZOLE; CYCLOBENZAPRINE; DASABUVIR; DIAZEPAM; HYDROCODONE BITARTRATE PLUS PARACETAMOL; METFORMIN; NORDAZEPAM; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; RITONAVIR; SULFONAMIDE; URACIL;

ADULT; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INTERACTION; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOMNOLENCE; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PHARMACOKINETICS; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEALTHY VOLUNTEERS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; PHARMACOKINETICS; RITONAVIR; SULFONAMIDES; URACIL; YOUNG ADULT;

EID: 84983080825     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-016-0373-8     Document Type: Article

References (35)

1. Patel N, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt LA, et al. A cross-sectional study comparing the frequency of drug interactions after adding simeprevir- or sofosbuvir-containing therapy to medication profiles of hepatitis C monoinfected patients. Infect Dis Ther. 2015;4:67–78.
2. Lauffenburger JC, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur J Gastroenterol Hepatol. 2014;26:1073–82.
3. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–603.
4. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–14.
5. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97 and 100 % sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147:359–65.
6. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82.
7. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–92.
8. Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L Jr, Setze C, et al. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced HCV-infected patients. Hepatology. 2015;61:1523–32.
9. Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502–9.
10. Menon RM, Klein CE, Podsadecki TJ, Chiu Y-L, Dutta S, Awni WM. Pharmacokinetics and tolerability of paritaprevir, a direct-acting antiviral agent for HCV treatment, with and without ritonavir in healthy volunteers. Br J Clin Pharmacol. 2016. doi:10.1111/bcp.12873
11. Bow DAJ, Liu J, Kavetskaia O, Menon R, de Morais SM, Nijsen M, et al. A mechanistic non-clinical assessment of drug-drug interactions (metabolism and transporters) with the hepatitis C virus (HCV) regimen: ABT-450/r, ombitasvir and dasabuvir [poster]. 2014 American Association for the Study of Liver Diseases/European Association for the Study of the Liver Special Conference on Hepatitis C; 12–13 Sep 2014; New York.
12. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother. 2008;42:1048–59.
13. Mensing S, Sharma S, Eckert D, Polepally A, Khatri A, Podsadecki T, et al. Pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in subjects with HCV genotype 1 infection in phase 3 studies. J Hepatol. 2015;62:S644.
14. Polepally AR, Badri P, Coakley EP, Parikh A, Rodrigues L Jr, DaSilva-Tillmann BA, et al. Effect of comedications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics [abstract no. 52]. Rev Antiviral Ther Infect Dis. 2015;4:56.
15. Badri PS, King JR, Polepally AR, McGovern BH, Dutta S, Menon RM. Dosing recommendations for concomitant medications during 3D anti-HCV therapy. Clin Pharmacokinet. 2015. doi:10.1007/s40262-015-0317-8 (Epub 2015 Sep 2).
16. ® (hydrocodone bitartrate/acetaminophen) tablets [package insert]. Whippany: Manufactured for AbbVie Inc. by Halo Pharmaceutical Inc.; 2013.
17. ® (diazepam) tablets [package insert]. Nutley: Roche Products Inc.; 2008.
18. Cyclobenzaprine hydrochloride tablets [package insert]. Salisbury: Jubilant Cadista Pharmaceuticals Inc.; 2013.
19. ® (carisoprodol) tablets [package insert]. Somerset: Meda Pharmaceuticals Inc.; 2013.
20. Bactrim™ (sulfamethoxazole/trimethoprim) [package insert]. Philadelphia: AR Scientific, Inc.; 2013.
21. ® (acetaminophen) tablets [professional product information]. Washington: McNeil Consumer Healthcare; 2010.
22. ® (metformin) [package insert]. Princeton: Bristol-Myers Squibb Company.; 2009.
23. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005;20:379–86.
24. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84:613–24.
25. Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol. 2013;6:249–69.
26. Polepally AR, Dutta S, Hu B, Podsadecki TJ, Awni WM, Menon RM. Drug-drug interaction of omeprazole with the HCV direct-acting antiviral agents paritaprevir/ritonavir and ombitasvir with and without dasabuvir. Clin Pharm Drug Develop. doi:10.1002/cpdd.246 (Epub 2016 Jan 24).
27. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther. 2003;74:275–87.
28. Tornio A, Niemi M, Neuvonen PJ, Backman JT. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab and Dispos. 2008;36:73–80.
29. Guidance for Industry: drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. Rockville: US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2012.
30. Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir and dasabuvir. J Hepatol. 2015;63:20–9.
31. ® (ritonavir) [package insert]. North Chicago: AbbVie, Inc.; 2015.
32. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368:45–53.
33. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370:222–32.
34. Badri PS, Dutta S, Wang H, Podsadecki TJ, Polepally AR, Khatri A, et al. Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir/ritonavir (2D regimen). Antimicrob Agents Chemother. 2015;60(1):105–14. doi:10.1128/AAC.01778-15.
35. Mensing S, Polepally A, Konig D, Khatri A, Liu W, Podsadecki T, et al. Population pharmacokinetics of ABT-450, ombitasvir, dasabuvir, ritonavir, and ribavirin in subjects with HCV genotype 1 infection. J Pharmacokinet Pharmacodyn. 2014;41:S42–3.